Free Half-Life Reference Table

77 compounds, one sourced table.

Elimination half-life for every compound in our catalog, each tagged with how solid the underlying data actually is — from FDA-label figures down to compounds with no published human data at all. Want to see this turned into a decay curve? Try the Half-Life Visualizer.

Compound	Half-Life	Evidence	Note

How to Use This Table

Built to be searched and filtered, not just scrolled.

Search or filterType a compound name to jump straight to it, or filter by evidence level to see only FDA-label-grade figures, for example.
Check the evidence tag before trusting a numberA number tagged "FDA label" or "clinical trial" is far more reliable than one tagged "limited" or "not characterized" — read the note column for why.
Read the note for contextMany entries have a specific caveat — a blend of two components with different clearance rates, a figure that varies by formulation, or a source that's mostly non-human data.
Model it visuallyOnce you have a half-life figure, plug it into the Half-Life Visualizer with your own dose and schedule to see an estimated decay curve.

Where This Data Comes From

Every figure is sourced from the best publicly available evidence for that specific compound — never presented with more confidence than the underlying research supports.

FDA label. The compound has an FDA-approved product with a package insert stating a specific half-life, based on that product's own clinical pharmacology studies. FDA prescribing information / package inserts.
Clinical trial data. The compound is investigational (not yet FDA-approved) but has published Phase 2/3 clinical-trial pharmacokinetic data. Published clinical trial protocols and results.
Published PK study. A peer-reviewed pharmacokinetic study exists in humans, even without full drug-approval status. Peer-reviewed pharmacokinetics literature.
Limited human data. Some human data exists but is sparse, from small studies, or shows a wide range across sources. Small or limited-scope published studies.
Not characterized in humans. No solid human plasma pharmacokinetic study was identified — any specific number circulating for these compounds typically traces back to animal studies, structural analogy to a related molecule, or vendor/community sources, not human trial data. Absence of published human PK literature; figures shown are the best available approximation and should be treated as rough estimates only.

Estimate only — not medical advice. Half-life figures vary by individual, formulation, administration route, and dose, and many entries in this table — especially those tagged "limited" or "not characterized" — are approximations from non-human or indirect sources. This table is reference information only, not medical advice, and not a substitute for consulting current literature or a licensed clinician.

Frequently Asked Questions

What does "half-life" actually mean?

Half-life is the time it takes for half of a substance to be eliminated from the body. It's a standard pharmacokinetic concept used to estimate how long a compound stays active and how often it typically needs to be dosed to maintain a steady level.

Why do some compounds have no half-life listed at all?

For a handful of research compounds (like Dihexa, Cerebrolysin, or MOTS-c), no published human pharmacokinetic study exists at all — we intentionally show no number rather than presenting an unsupported guess as if it were solid data.

Why do half-life estimates vary so much between sources online?

Because study quality, population, dose, and route of administration all affect measured half-life, and many peptides — especially unapproved research compounds — have only ever been studied in animals or in very small human samples. Numbers you see elsewhere may trace back to a single small study, a structural analogy to a related compound, or informal community reporting.

What's the difference between "clinical trial data" and "published PK study" tags?

"Clinical trial data" means the compound is still investigational and the figure comes from a trial's own reported pharmacokinetics. "Published PK study" means a standalone peer-reviewed pharmacokinetic study exists, independent of a specific drug-approval trial — both are solid, but represent slightly different kinds of evidence.

Can I use this table to predict my own blood levels?

No. This table shows population-level half-life estimates from published sources — it says nothing about your individual absorption, metabolism, kidney or liver function, or how a specific compound behaves in your body specifically. Individual variation can be substantial.

Why do blend entries (like a CJC-1295/Ipamorelin blend) show one number for two compounds?

A blend combines compounds that clear the body at different rates. Where we show one number for a blend, it typically reflects the shorter or more commonly emphasized component — check the note column, which flags this explicitly for each blend.

Is a longer half-life better or worse?

Neither — it depends entirely on what you're trying to achieve. A longer half-life generally means steadier levels between doses and less frequent dosing; a shorter half-life means levels rise and fall faster, which some protocols intentionally use (e.g. a short-acting growth-hormone secretagogue dosed around a specific time of day).

How is this different from the Half-Life Visualizer?

This page is a static reference table. The Half-Life Visualizer takes any compound's half-life and your own dose/schedule to draw an actual estimated decay curve with peak, trough and steady-state figures.

Where can I read the original research behind a specific figure?

This table cites source types (FDA labels, clinical trials, PK studies) rather than individual paper links, since sourcing spans dozens of documents. For a specific compound, searching that compound's name alongside "pharmacokinetics" or "half-life" in a source like PubMed will typically surface the underlying literature.